Table 1 Ibrutinib in clinical trials for chronic lymphoid leukemia
| Studies | Phase Ib/II for CLL/SLL | Phase Ib/II for CLL patients (N=116) [26] | Ibrutinib | Ibrutinib | ||
|---|---|---|---|---|---|---|
| + | + | |||||
| Rituximab | Ofatumumab | |||||
| (High risk refractory/relapsed) | Treatment naïve patients >65 years old | Relapsed/refractory | High risk relapsed/refractory | (Relapsed/refractory CLL) | (Relapsed/refractory CLL) | |
| [N=85] [24] | [N=40] [40] | [N=40] [41] | ||||
| ORR | 71% | 71% (CR=10%, PR=61%) | 67 % (CR=3%, PR=64%) | 50% (PR=50%, CR=0%) | 85% | 100% |